Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
BACKGROUND: Colorectal polyp burden is crucial for the management of patients with familial adenomatous polyposis (FAP). However, accurate evaluation of polyp burden is difficult to standardize. This study aimed to examine the possible utility of genotype-oriented management of colorectal neoplasms in patients with FAP.
METHODS: Clinicopathological data from genetically proven patients with FAP was analyzed using the database of a nationwide retrospective Japanese multicenter study. The cumulative incidence of CRC was evaluated between different genotype groups. Genotype-1 were defined as germline variants on attenuated FAP-associated regions (codons 1-177, alternative splice site of exon 10 (codon 312), 1581-2843) and Genotype-2 as the other variants. Weibull and Joinpoint analyses were performed to determine the annual percentage changes in CRC risk.
RESULTS: Overall, 69 men and 102 women were included. Forty-eight patients underwent colorectal resection for the first CRC, and five patients underwent resection for first cancer in the remnant anorectal segment after prophylactic surgery. The 70-year cumulative incidence of CRC in all patients was 59.3%. Patients with Genotype-1 (n = 23) demonstrated a lower risk of CRC stages II-IV than those with Genotype-2 (n = 148, P = 0.04). The risk of stage II-IV CRC was estimated to increase markedly at the age of 49 years in the Genotype-1 patients and 34 years in the Genotype-2 patients, respectively.
CONCLUSIONS: Different interventional strategies based on genotypes may be proposed for the clinical management of patients with FAP. This policy needs to be validated in further prospective studies focusing on long-term endoscopic intervention and optimal age at prophylactic (procto)colectomy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 28(2023), 12 vom: 18. Dez., Seite 1641-1650 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mori, Yoshiko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenomatous polyposis coli gene |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 01.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-023-02419-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363457801 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363457801 | ||
| 003 | DE-627 | ||
| 005 | 20231226093406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-023-02419-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363457801 | ||
| 035 | |a (NLM)37853284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mori, Yoshiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a BACKGROUND: Colorectal polyp burden is crucial for the management of patients with familial adenomatous polyposis (FAP). However, accurate evaluation of polyp burden is difficult to standardize. This study aimed to examine the possible utility of genotype-oriented management of colorectal neoplasms in patients with FAP | ||
| 520 | |a METHODS: Clinicopathological data from genetically proven patients with FAP was analyzed using the database of a nationwide retrospective Japanese multicenter study. The cumulative incidence of CRC was evaluated between different genotype groups. Genotype-1 were defined as germline variants on attenuated FAP-associated regions (codons 1-177, alternative splice site of exon 10 (codon 312), 1581-2843) and Genotype-2 as the other variants. Weibull and Joinpoint analyses were performed to determine the annual percentage changes in CRC risk | ||
| 520 | |a RESULTS: Overall, 69 men and 102 women were included. Forty-eight patients underwent colorectal resection for the first CRC, and five patients underwent resection for first cancer in the remnant anorectal segment after prophylactic surgery. The 70-year cumulative incidence of CRC in all patients was 59.3%. Patients with Genotype-1 (n = 23) demonstrated a lower risk of CRC stages II-IV than those with Genotype-2 (n = 148, P = 0.04). The risk of stage II-IV CRC was estimated to increase markedly at the age of 49 years in the Genotype-1 patients and 34 years in the Genotype-2 patients, respectively | ||
| 520 | |a CONCLUSIONS: Different interventional strategies based on genotypes may be proposed for the clinical management of patients with FAP. This policy needs to be validated in further prospective studies focusing on long-term endoscopic intervention and optimal age at prophylactic (procto)colectomy | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adenomatous polyposis coli gene | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Familial adenomatous polyposis | |
| 650 | 4 | |a Genotype | |
| 700 | 1 | |a Ishida, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Chika, Noriyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Amano, Kunihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Chikatani, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Kono, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shichijo, Satoki |e verfasserin |4 aut | |
| 700 | 1 | |a Chino, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nagasaki, Toshiya |e verfasserin |4 aut | |
| 700 | 1 | |a Takao, Akinari |e verfasserin |4 aut | |
| 700 | 1 | |a Takao, Misato |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamori, Sakiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Akagi, Kiwamu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Tatsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Tanakaya, Kohji |e verfasserin |4 aut | |
| 700 | 1 | |a Naohiro, Tomita |e verfasserin |4 aut | |
| 700 | 1 | |a Ajioka, Yoichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 28(2023), 12 vom: 18. Dez., Seite 1641-1650 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:12 |g day:18 |g month:12 |g pages:1641-1650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-023-02419-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 12 |b 18 |c 12 |h 1641-1650 | ||